strateg collabor novo
set new
rais pt
collab novo up-front equiti roch
up-front demonstr abil particip larger deal upsid
option opt-in structur co-develop co-commerci
larger econom role long-term view becom larger platform
play similar nr nr
deal add signific cash fund intern partner
program note key catalyst data dcr-hbv
poc data
pleas see transfer report
strateg novo nordisk novo b-dk nr collabor allow
addit core program ad pipelin
opt-in right co-develop co-fund program exchang co-
first year collabor per target
mileston payment plu tier royalti rang mid-single-digit
mid-teen product sale
similar roch rog-ch nr collabor novo deal allow
opt-in featur deal allow clinic opt-in addit
rare diseas carve-out novo opt-in two opt-in rate
exercis clinic data review first phase first phase
recent roch novo collabor larger scope valu
allow right opt-in co-develop co-fund develop
exchang co-commerci role remind prior deal bi
privat nr buy nomin target gener
licens
cash addit cash infus up-front
roch up-front equiti invest novo give
note key catalyst includ read-thru
dcr-hbv poc data
tr target
updat model reflect addit cash expens addit program arriv
pt
page
figur million dollar except per share data
strh research compani report updat
page
incom product oper itemsnet interest incom incom provis net redeem convert prefer dividend relat benefici dividend convers redeem convert prefer net incom avail common ep ep chang non- provis tax net ep ep share share dicerna pharmaceut inc
dicerna clinic stage biotech compani proprietari platform technolog focus rnai
therapeut compani one program phase clinic develop two addit
program enter clinic dcr-phxc dicerna lead rnai-bas drug candid
primari hyperoxaluria diseas direct therapeut option patient often progress end-
stage renal diseas kidney failur given breadth compani technolog platform
dicerna chosen pursu certain diseas area alon addit partner diseas
area would requir greater fund commerci resourc fulli develop
rate buy believ compani valid rnai platform play cash runway
sever partnership bring sever trial clinic across multipl indic
valuat risk
rate buy pt appli discount rate line
smid cap termin growth rate believ compani valid rnai
platform play cash runway sever partnership bring sever trial clinic across multipl
risk clinic risk dcr-phxc data provid sustain respons ph program
delay dcr-hbv poc data hold
compani mention note
compani nr
robyn karnauska herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
suntrust robinson humphrey inc make market follow compani drna-u alxn-u
analyst compens base upon stock price perform qualiti analysi commun skill
overal revenu profit firm includ invest bank revenu
matter polici practic firm prohibit offer favor research specif
research rate specif target price consider induc receipt busi
compens addit associ person prepar research report prohibit own
secur subject compani
page
rate price target histori inc drna-u
rate price target histori inc alxn-u
creat bluematrix
creat bluematrix
strh rate system equiti secur
dissemin research
suntrust robinson humphrey strh seek make reason effort provid research report
simultan elig client report avail publish restrict access area
websit elig client request password institut investor corpor
member press may also receiv research via third parti vendor includ thomson reuter
bloomberg factset capit iq addit distribut may done sale personnel via
email fax electron mean regular mail
access third parti vendor research websit http //suntrustlibrari bluematrix com/client/
pleas email research depart
contact strh sale repres
strh rate equiti secur
rate rel broader market gener next month unless
buy stock total return expect outperform relev benchmark
hold stock total return expect perform line relev benchmark
next month unless otherwis indic
sell stock total return expect under-perform relev benchmark
next month unless otherwis indic
rate nr strh invest rate opinion stock
page
coverag suspend cs indic strh rate and/or target price temporarili
suspend due applic regul and/or strh manag discret previous publish
rate target price reli upon
strh analyst price target stock cover unless otherwis indic price
target repres analyst expect stock trade next month unless
otherwis indic analyst believ insuffici valuat driver and/or invest
catalyst deriv posit neg invest view may elect approv strh
research manag assign target price likewis certain stock trade may
exhibit volatil wherebi assign price target would unhelp make invest decis
research manag approv analyst may refrain assign target sub-
legend rate price target histori chart
suntrust robinson humphrey rate distribut
